Table of Contents  

Discovery of first-in-class therapeutics – venlafaxine (Effexor®), desvenlafaxine (Pristiq®), temsirolimus (Toresil®), ILS-920 and gemtuzumab ozogamicin (Mylotarg®)

Magid Abou-Gharbia
Published in : HAMDAN MEDICAL JOURNAL ; Vol 7, No 3 (2014)
DOI : 10.7707/hmj.346


The pharmaceutical industry today is experiencing unprecedented difficulty and faces enormous challenges, which include the industrys declining efficiencies, patent expirations for key drugs, fierce price competition from generic drugs, mergers and acquisitions, high regulatory hurdles, declining innovation and the industrys perceived tarnished image. Pharma has embarked on a range of initiatives to address these challenges, maintain its commitment to innovation and continue its mission to alleviate human suffering through the discovery of new medicines. This review covers the following themes: (1) drug discovery highlighting process, targets, approach and current pharmaceutical platforms (small molecules, biologics and vaccines); (2) todays realities highlighting current challenges facing the pharmaceutical industry, especially the innovation gap, and Pharmas commitment to innovation; (3) commitment to innovation and success stories focusing on selected examples of first-in-class therapeutics, such as the serotoninnoradrenaline reuptake inhibitor antidepressants venlafaxine (Effexor®, Pfizer, Surrey, UK) and desvenlafaxine (Pristiq®, Pfizer, Surrey, UK), immunophilin mammalian target of rapamycin modulator temsirolimus (Toresil®, Pfizer, Surrey, UK), the neuroprotectant ILS-920 for stroke therapy and the first conjugate anticancer drug gemtuzumab ozogamicin (Mylotarg®, Pfizer, Surrey, UK). Although many high drug discovery hurdles remain, the future holds great promise. The search continues for major breakthrough therapies that address unmet medical needs, such as disease-halting drugs for the treatment of Alzheimers disease, drugs to eradicate hepatitis C and acquired immune deficiency syndrome, and drugs to attack resistant cancers, treat strokes and alleviate cardiovascular disease.

View article in  :   PDF     HTML    

Add comment 

Home  Editorial Board  Search  Current Issue  Archive Issues  Announcements  Aims & Scope  About the Journal  How to Submit  Contact Us
Find out how to become a part of the HMJ  |   CLICK HERE >>
© Copyright 2012 - 2013 HMJ - HAMDAN Medical Journal. All Rights Reserved         Website Developed By Cedar Solutions INDIA